Biomarkers for Huntington's disease

Expert Opinion on Medical Diagnostics

Volumn 2, Issue 1, 2008, Pages 47-62

  Wild, Edward J ^a   Tabrizi, Sarah J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarkers; Huntington's disease

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ADENOSINE RECEPTOR; AMYLOID BETA PROTEIN; ANANDAMIDE; ARYLBUTYRIC ACID DERIVATIVE; BRAIN DERIVED NEUROTROPHIC FACTOR; CLUSTERIN; COPPER ZINC SUPEROXIDE DISMUTASE; CREATINE; CYSTAMINE; ENDOCANNABINOID; FATTY ACID AMIDASE; GHRELIN; GLUTATHIONE PEROXIDASE; HUNTINGTIN; HYDROCORTISONE; IMMEDIATE EARLY PROTEIN; INTERLEUKIN 6; ISOLEUCINE; LEPTIN; LEUCINE; MALONALDEHYDE; MERCAPTAMINE; TESTOSTERONE; VALINE;

ACTIMETRY; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; BRAIN ATROPHY; BRAIN CORTEX; CELL LEVEL; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITION; CONCEPTUAL FRAMEWORK; COURSE EVALUATION; DIFFUSION TENSOR IMAGING; DRUG PENETRATION; EYE MOVEMENT CONTROL; FINGER; FUNCTIONAL ASSESSMENT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GAIT; GENE MUTATION; GRIP STRENGTH; HETEROZYGOTE; HORMONE BLOOD LEVEL; HUMAN; HUNTINGTON CHOREA; MOTOR CONTROL; MOTOR PERFORMANCE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; REVIEW; STRIATE CORTEX; TESTOSTERONE BLOOD LEVEL; TISSUE STRUCTURE; TONGUE; URINE LEVEL; VOLUMETRY;

EID: 57749170032     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2.1.47     Document Type: Review

References (111)

1. Bates G, Harper PS, Jones L. Huntington's Disease. Third edition, Oxford University Press: Oxford; 2002. p. 558
2. Handley OJ, Naji JJ, Dunnett SB, et al. Pharmaceutical, cellular and genetic therapies for Huntington's disease. Clin Sci 2006;110:73-88 (Pubitemid 43059046)
3. The Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord 1996;11:136-142
4. Wild EJ, Tabrizi SJ. Predict-HD and the future of therapeutic trials. Lancet Neurol 2006;5:724-725 (Pubitemid 44209398)
5. Paulsen JS, Hayden M, Stout JC, et al. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 2006;63:883-890 (Pubitemid 43882298)
6. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95 (Pubitemid 32225406)
7. Fox NC, Black RS, Gilman S, et al. Effects of A{beta} immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005;64:1563-1572 (Pubitemid 40617692)
8. Delta Coordinating Committee. Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: delta extended follow-up. HIV Med 2001;2:181-188 (Pubitemid 33114762)
9. Henley SM, Bates GP, Tabrizi SJ. Biomarkers for neurodegenerative diseases. Curr Opin Neurol 2005;18:698-705 (Pubitemid 41669144)
10. Aylward EH, Rosenblatt A, Field K, et al. Caudate volume as an outcome measure in clinical trials for Huntington's disease: a pilot study. Brain Res Bull 2003;62:137-141 (Pubitemid 37443659)
11. Rosas HD, Hevelone ND, Zaleta AK, et al. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005;65:745-747 (Pubitemid 41285856)
12. Henley SMD, Frost C, MacManus DG, et al. Increased rate of whole-brain atrophy over 6 months in early Huntington disease. Neurology 2006;67:694-696 (Pubitemid 44273624)
13. Rosas HD, Tuch DS, Hevelone ND, et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Mov Disord 2006;21:1317-1325 (Pubitemid 44613279)
14. Hennenlotter A, Schroeder U, Erhard P, et al. Neural correlates associated with impaired disgust processing in pre-symptomatic Huntington's disease. Brain 2004;127:1446-1453 (Pubitemid 38745522)
15. Pavese N, Andrews TC, Brooks DJ, et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 2003;126:1127-1135 (Pubitemid 36522955)
16. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 1986;9:357-381 (Pubitemid 16055790)
17. Harris GJ, Pearlson GD, Peyser CE, et al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease. Ann Neurol 1992;31:69-75
18. Aylward EH, Brandt J, Codori AM, et al. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 1994;44:823-828 (Pubitemid 24158794)
19. Aylward EH, Codori AM, Barta PE, et al. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol 1996;53:1293-1296 (Pubitemid 26425076)
20. Brandt J, Bylsma FW, Aylward EH, et al. Impaired source memory in Huntington's disease and its relation to basal ganglia atrophy. J Clin Exp Neuropsychol 1995;17:868-877 (Pubitemid 26020988)
21. Aylward EH, Li Q, Stine OC, et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 1997;48:394-399 (Pubitemid 27087610)
22. Aylward EH, Codori AM, Rosenblatt A, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord 2000;15:552-560 (Pubitemid 30333230)
23. Aylward EH, Sparks BF, Field KM, et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004;63:66-72 (Pubitemid 38943780)
24. Rosas HD, Goodman J, Chen YI, et al. Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology 2001;57:1025-1028 (Pubitemid 32880197)
25. Hobbs NZ, Henley SM, Barnes J, et al. Increased Caudate Atrophy Rates in Huntington's Disease and Premanifest Subjects: A Novel Semiautomated Technique. World Congress on Huntington's Disease, 2007 ; Dresden, Germany. Available at: URL: www.worldcongress-hd.net [last accessed December 2007]
26. Rosas HD, Feigin AS, Hersch SM. Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease. NeuroRx 2004;1:263-272 (Pubitemid 46591885)
27. Rosas HD, Koroshetz WJ, Chen YI, et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003;60:1615-1620 (Pubitemid 36618087)
28. Rosas HD, Liu AK, Hersch S, et al. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002;58:695-701 (Pubitemid 34211546)
29. Freeborough PA, Fox NC. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imaging 1997;16:623-629 (Pubitemid 127767641)
30. Kassubek J, Juengling FD, Ecker D, et al. Thalamic atrophy in Huntington's disease co-varies with cognitive performance: a morphometric MRI analysis. Cereb Cortex 2005;15:846-853 (Pubitemid 40696123)
31. Kassubek J, Juengling FD, Kioschies T, et al. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry 2004;75:213-220 (Pubitemid 38183526)
32. Thieben MJ, Duggins AJ, Good CD, et al. The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain 2002;125:1815-1828 (Pubitemid 34885709)
33. Kipps CM, Duggins AJ, Mahant N, et al. Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study. J Neurol Neurosurg Psychiatry 2005;76:650-655 (Pubitemid 40569674)
34. Werring DJ, Clark CA, Barker GJ, et al. Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology 1999;52:1626-1632 (Pubitemid 29220638)
35. Reading SAJ, Yassa MA, Bakker A, et al. Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiatry Res Neuroimaging 2005;140:55-62 (Pubitemid 41443496)
36. Clark VP, Lai S, Deckel AW. Altered functional MRI responses in Huntington's disease. Neuroreport 2002;13:703-706 (Pubitemid 34293495)
37. Thiruvady DR, Georgiou-Karistianis N, Egan GF, et al. Functional connectivity of the prefrontal cortex in Huntington's disease. J Neurol Neurosurg Psychiatry 2007;78:127-133 (Pubitemid 46220207)
38. Aron AR, Schlaghecken F, Fletcher PC, et al. Inhibition of subliminally primed responses is mediated by the caudate and thalamus: evidence from functional MRI and Huntington's disease. Brain 2003;126:713-723 (Pubitemid 36240871)
39. Paulsen JS, Zimbelman JL, Hinton SC, et al. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's disease. AJNR Am J Neuroradiol 2004;25:1715-1721 (Pubitemid 44123696)
40. Gavazzi C, Nave RD, Petralli R, et al. Combining functional and structural brain magnetic resonance imaging in Huntington disease. J Comput Assist Tomogr 2007;31:574-580 (Pubitemid 47457673)
41. Jenkins BG, Rosas HD, Chen YC, et al. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 1998;50:1357-1365 (Pubitemid 28240352)
42. Reynolds NC Jr, Prost RW, Mark LP. Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease. Brain Res 2005;1031:82-89 (Pubitemid 40038366)
43. Koroshetz WJ, Jenkins BG, Rosen BR, et al. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 1997;41:160-165 (Pubitemid 27082096)
44. Hoang TQ, Bluml S, Dubowitz DJ, et al. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology 1998;50:1033-1040 (Pubitemid 28212834)
45. Sanchez-Pernaute R, Garcia-Segura JM, del Barrio Alba A, et al. Clinical correlation of striatal 1H MRS changes in Huntington's disease. Neurology 1999;53:806-812 (Pubitemid 29448304)
46. Hersch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 2006;66:250-252 (Pubitemid 43970166)
47. Cross A, Rossor M. Dopamine D-1 and D-2 receptors in Huntington's disease. Eur J Pharmacol 1983;88:223-229
48. Turjanski N, Weeks R, Dolan R, et al. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain 1995;118(Pt 3):689-696
49. Ginovart N, Lundin A, Farde L, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 1997;120(Pt 3):503-514 (Pubitemid 27153642)
50. Weeks RA, Piccini P, Harding AE, et al. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol 1996;40:49-54 (Pubitemid 26250142)
51. Antonini A, Leenders KL, Eidelberg D. [11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol 1998;43:253-255 (Pubitemid 28110128)
52. van Oostrom JCH, Maguire RP, Verschuuren-Bemelmans CC, et al. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology 2005;65:941-943 (Pubitemid 41362149)
53. Lawrence AD, Weeks RA, Brooks DJ, et al. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. Brain 1998;121(Pt 7):1343-1355 (Pubitemid 28327410)
54. Andrews TC, Weeks RA, Turjanski N, et al. Huntington's disease progression. PET and clinical observations. Brain 1999;122(Pt 12):2353-2363
55. Furtado S, Sossi V, Hauser RA, et al. Positron emission tomography after fetal transplantation in Huntington's disease. Ann Neurol 2005;58:331-337 (Pubitemid 41098893)
56. Messmer K, Reynolds GP. Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease. Neurosci Lett 1998;241:53-56 (Pubitemid 28079032)
57. Sapp E, Kegel KB, Aronin N, et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 2001;60:161-172 (Pubitemid 32172419)
58. Giorgini F, Guidetti P, Nguyen Q, et al. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet 2005;37:526-531 (Pubitemid 40617282)
59. Pavese N, Gerhard A, Tai YF, et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 2006;66:1638-1643 (Pubitemid 43964614)
60. Tai YF, Pavese N, Gerhard A, et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 2007;130:1759-1766 (Pubitemid 47343790)
61. Nordberg A. Amyloid imaging in Alzheimer's disease. Curr Opin Neurol 2007;20:398-402 (Pubitemid 47051985)
62. Ciammola A, Sassone J, Cannella M, et al. Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients. Am J Med Genet B Neuropsychiatr Genet 2007;144B:574-577 (Pubitemid 46983172)
63. Borovecki F, Lovrecic L, Zhou J, et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci USA 2005;102:11023-11028 (Pubitemid 41105986)
64. Runne H, Kuhn A, Wild EJ, et al. Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. Proc Natl Acad Sci USA 2007;104(36):14424-14429 (Pubitemid 350003277)
65. Dalrymple A, Wild EJ, Joubert R, et al. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res 2007;6:2833-2840 (Pubitemid 47122377)
66. Wild EJ, Petzold A, Keir G, et al. Plasma neurofilament heavy chain levels in Huntington's disease. Neurosci Lett 2007;417:231-233 (Pubitemid 46589785)
67. Chen CM, Wu YR, Cheng ML, et al. Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. Biochem Biophys Res Commun 2007;359:335-340 (Pubitemid 46880509)
68. Underwood BR, Broadhurst D, Dunn WB, et al. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 2006;129:877-886
69. Mochel F. Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One 2007;2:e647 (Pubitemid 351314890)
70. Valenza M, Rigamonti D, Goffredo D, et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci 2005;25:9932-9939 (Pubitemid 41528031)
71. Runne H, Kuhn A, Wild EJ, et al. Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. Proc Natl Acad Sci USA 2007;104:14424-14429 (Pubitemid 350003277)
72. Battista N, Bari M, Tarditi A, et al. Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes. Neurobiol Dis 2007;27:108-116 (Pubitemid 46924866)
73. Varani K, Bachoud-Levi AC, Mariotti C, et al. Biological abnormalities of peripheral A(2A) receptors in a large representation of polyglutamine disorders and Huntington's disease stages. Neurobiol Dis 2007;27:36-43. (Pubitemid 46924865)
74. Bjorkqvist M, Petersen A, Bacos K, et al. Progressive alterations in the hypothalamic- pituitary- adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum Mol Genet 2006;15:1713-1721 (Pubitemid 43904837)
75. Popovic V, Svetel M, Djurovic M, et al. Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease. Eur J Endocrinol 2004;151:451-455 (Pubitemid 39430262)
76. Markianos M, Panas M, Kalfakis N, et al. Plasma testosterone in male patients with Huntington's disease: relations to severity of illness and dementia. Ann Neurol 2005;57:520-525 (Pubitemid 40471161)
77. Bjorkqvist M, Leavitt BR, Nielsen JE, et al. Cocaine- and amphetamine-regulated transcript is increased in Huntington disease. Mov Disord 2007 ;22(13):1952-1954 (Pubitemid 350134210)
78. Bogdanov MB, Andreassen OA, Dedeoglu A, et al. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J Neurochem 2001;79:1246-1249 (Pubitemid 34019802)
79. Biglan K, Dorsey ER, Kieburtz K, et al. Serum 8OHdG Levels in Manifest Huntington's Disease and Healthy Controls Treated with Coenzyme Q10. World Congress on Huntington's Disease, 2007;Dresden, Germany. Available at: URL: www.worldcongress-hd.net [last accessed December 2007]
80. Liu CS, Cheng WL, Kuo SJ, et al. Depletion of mitochondrial DNA in leukocytes of patients with poly-Q diseases. J Neurol Sci 2008;264(1-2):18-21 (Pubitemid 350184064)
81. Farrer LA, Meaney FJ. An anthropometric assessment of Huntington's disease patients and families. Am J Phys Anthropol 1985;67:185-194 (Pubitemid 15027364)
82. Phillipson OT, Bird ED. Plasma glucose, non-esterified fatty acids and amino acids in Huntington's chorea. Clin Sci Mol Med 1977;52:311-318
83. Cha JH. Transcriptional dysregulation in Huntington's disease. Trends Neurosci 2000;23:387-392 (Pubitemid 30674167)
84. Strand AD, Aragaki AK, Shaw D, et al. Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum Mol Genet 2005;14:1863-1876 (Pubitemid 41418057)
85. Ferrer I, Goutan E, Marin C, et al. Brain-derived neurotrophic factor in Huntington disease. Brain Res 2000;866:257-261 (Pubitemid 30313028)
86. Borrell-Pages M, Canals JM, Cordelieres FP, et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 2006;116:1410-1424
87. Lommatzsch M, Zingler D, Schuhbaeck K, et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 2005;26:115-123 (Pubitemid 39600596)
88. Lastres-Becker I, De Miguel R, Fernandez-Ruiz JJ. The endocannabinoid system and Huntington's disease. Curr Drug Targets CNS Neurol Disord 2003;2:335-347
89. Varani K, Rigamonti D, Sipione S, et al. Aberrant amplification of A(2A) receptor signaling in striatal cells expressing mutant huntingtin. FASEB J 2001;15:1245-1247
90. Varani K, Abbracchio MP, Cannella M, et al. Aberrant A2A receptor function in peripheral blood cells in Huntington's disease. FASEB J 2003 ;17(14):2148-2150
91. Petersen A, Bjorkqvist M. Hypothalamic-endocrine aspects in Huntington's disease. Eur J Neurosci 2006;24:961-967 (Pubitemid 44268127)
92. Markianos M, Panas M, Kalfakis N, et al. Plasma testosterone, dehydroepiandrosterone sulfate, and cortisol in female patients with Huntington's disease. Neuro Endocrinol Lett 2007;28:199-203 (Pubitemid 46739073)
93. Golding CV, Danchaivijitr C, Hodgson TL, et al. Identification of an oculomotor biomarker of preclinical Huntington disease. Neurology 2006;67(3):485-487 (Pubitemid 44214975)
94. Ali FR, Michell AW, Barker RA, et al. The use of quantitative oculometry in the assessment of Huntington's disease. Exp Brain Res 2006;169:237-245 (Pubitemid 43221149)
95. Gordon AM, Quinn L, Reilmann R, et al. Coordination of prehensile forces during precision grip in Huntington's disease. Exp Neurol 2000;163:136-148 (Pubitemid 30314368)
96. Hurelbrink CB, Lewis SJG, Barker RA. The use of the Actiwatch- Neurologica® system to objectively assess the involuntary movements and sleep-wake activity in patients with mild-moderate Huntington's disease. J Neurol 2005;252:642-647 (Pubitemid 40864036)
97. Blekher TM, Yee RD, Kirkwood SC, et al. Oculomotor control in asymptomatic and recently diagnosed individuals with the genetic marker for Huntington's disease. Vision Res 2004;44:2729-2736 (Pubitemid 39092500)
98. Saft C, Andrich J, Meisel NM, et al. Assessment of simple movements reflects impairment in Huntington's disease. Mov Disord 2006;21:1208-1212 (Pubitemid 44336609)
99. Andrich J, Saft C, Ostholt N, et al. Assessment of simple movements and progression of Huntington's disease. J Neurol Neurosurg Psychiatry 2007;78:405-407 (Pubitemid 46580553)
100. Hinton SC, Paulsen JS, Hoffmann RG, et al. Motor timing variability increases in preclinical Huntington's disease patients as estimated onset of motor symptoms approaches. J Int Neuropsychol Soc 2007;13:539-543 (Pubitemid 47307494)
101. Reilmann R, Kirsten F, Quinn L, et al. Objective assessment of progression in Huntington's disease: a 3-year follow-up study. Neurology 2001;57:920-924 (Pubitemid 32845525)
102. Reilmann R, Bohlen S, Kirsten F, et al. Grip-Force Variability in Asymptomatic Carriers of the Huntington Gene - A Biomarker for Presymptomatic Clinical Studies? American Academy of Neurology Annual Meeting, 2007; Boston, MA, USA. Available at: URL: www.aan.com [last accessed December 2007]
103. van Vugt JP, Siesling S, Piet KK, et al. Quantitative assessment of daytime motor activity provides a responsive measure of functional decline in patients with Huntington's disease. Mov Disord 2001;16:481-488 (Pubitemid 36041152)
104. Rao AK, Quinn L, Marder KS. Reliability of spatiotemporal gait outcome measures in Huntington's disease. Mov Disord 2005;20:1033-1037 (Pubitemid 41419522)
105. Thanendrarajan S, Hoffmann A, Landwehrmeyer GB, et al. Computer-aided analysis of drawing movements in Huntington patients: graphimetry. World Congress on Huntington's Disease, 2007; Dresden, Germany. Available at: URL: www.worldcongress-hd.net [last accessed December 2007]
106. Bohlen S, Kirsten F, Auer D, et al. Assessment of motor phenotype in symptomatic Huntington's disease - is tongue protrusion force analysis an objective surrogate marker? American Academy of Neurology Annual Meeting, 2007; Boston, MA, USA. Available at: URL: www.aan.com [last accessed December 2007]
107. Craufurd D, Snowden J, Neuropsychological and Neuropsychiatric Aspects of Huntington's Disease, in Huntington's Disease, PS Harper, editor, Oxford Medical Publications: Oxford; 2002
108. Huntington Study Group. Clinical Trials & Research Studies in Progress. Available at: URL: www.huntington-study-group.org [last accessed 3 October 2007]
109. European Huntington's Disease Network. EHDN Registry. Available at: URL: www.euro-hd.net [last accessed 3 October 2007]
110. HD Toolkit. Available at: URL: www.indiana.edu/~ccns/research-hdtk.html [last accessed 3 October 2007]
111. TRACK-HD. Available at: URL: www.track-hd.net [last accessed 3 October 2007]